Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022;22(1):10-18.
doi: 10.24911/SJP.106-1621869672.

Measles, mumps and rubella vaccine and heterologous immunity: a way out of the COVID-19 crisis?

Jahnavi Shrivastava  1 , Manish Narang  1 , Sunil Gomber  1
Affiliations
Review

Measles, mumps and rubella vaccine and heterologous immunity: a way out of the COVID-19 crisis?

Jahnavi Shrivastava et al. Sudan J Paediatr. 2022.

Abstract

Heterologous immunity is a well-known concept in immunology wherein prior exposure to an antigen confers cross-protection against an unrelated antigen. With the surge in global COVID-19 cases, there has been significant research into the application of vaccine-induced heterologous immunity associated with measles, mumps and rubella (MMR) vaccine, Bacillus Calmette-Guérin vaccine, oral polio vaccine, and hepatitis A vaccine in curbing the worst outcomes of COVID-19 infection. Despite having specific vaccines against COVID-19, it is worthwhile exploring the application of available vaccines in the prevention of severe disease until the vaccines reach all sections of the population across the globe. In this article, we aim to outline the concept of heterologous immunity and its relevance in context to MMR vaccine and COVID-19.

Keywords: COVID-19; Children; Heterologous immunity; MMR vaccine; Prophylaxis; Trained immunity; Vaccination.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflict of interest.

References

    1. Welsh RM, Che JW, Brehm MA, Selin LK. Heterologous immunity between viruses. Immunol Rev. 2010;235:244–66. https://doi.org/10.1111/j.0105-2896.2010.00897.x. - PMC - PubMed
    1. Welsh R, Fujinami R. Pathogenic epitopes, heterologous immunity and vaccine design. Nat Rev Microbiol. 2007;5:555–63. https://doi.org/10.1038/nrmicro1709. - PMC - PubMed
    1. Dhochak N, Singhal T, Kabra SK, Lodha R. Pathophysiology of COVID-19: why children fare better than adults? Indian J Pediatr. 2020;87:537–46. https://doi.org/10.1007/s12098-020-03322-y. - PMC - PubMed
    1. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 among children in China. Pediatrics. 2020;145:e20200702. https://doi.org/10.1542/peds.2020-0702. - PubMed
    1. Selin LK, Varga SM, Wong IC, Welsh RM. Protective heterologous antiviral immunity and enhanced immunopathogenesis mediated by memory T cell populations. J Exp Med. 1998;188:1705–15. https://doi.org/10.1084/jem.188.9.1705. - PMC - PubMed

LinkOut - more resources